Global Gaucher Disease Drugs Market, by Type (Type 1, Type 2, and Type 3), by Therapy (Enzyme Replacement Therapy and Substrate Replacement Therapy) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.
Gaucher disease refers to a state of disorder of gene, where the body fat gets accumulated into the tissues or certain organs. It is mainly caused by the deficiency of an enzyme, named B-glucocerebrosidase; this state can further result into fatigue, low blood platelet count, bruising, etc. this disease is also characterized by the enlargement of liver and spleen; and is more likely to affect children than adults. As per the report, the elevated demand for efficient and well controlled treatment is the prime factor driving the market growth. Also, the factors like elevated count of developed drugs and their approvals, growing efforts for the identification of patients suffering from Gaucher disease, increasing disposable income, etc. are also responsible for favouring the Gaucher disease drug market during the upcoming years. Moreover, increasing government’s initiatives to promote the awareness about this disease also stimulates the market growth; like the European Gaucher Alliance launched a Gaucher awareness day to acknowledge their citizens about Gaucher and its effects. However, the rare nature of the Gaucher disease along with the high cost associated with its treatment are likely to restrain the growth of global Gaucher disease drug market.
Global Gaucher disease drug market is segmented into three sections, namely, by type, therapy and region. On the basis of type, this market is fragmented into Type 1, Type 2, and Type 3. Whereas, the therapy segment is sectioned as Enzyme Replacement Therapy and Substrate Replacement Therapy. Lastly, on the basis of regions, this market is divided into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
MMC Study also identifies some of the key participating players of Gaucher disease drugs market globally as Sanofi Genzyme, Shire Human Genetics Therapies, Inc., Pfizer, Inc., and Johnson & Johnson.
